YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 333 drug applications between 15 November 2026 and 21 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 57, covering 41 drug names.

2026/11/15 – 2026/11/21

Period
2026/11/15 to 2026/11/21, 7 days inclusive
Data as of
2026/11/23
Loaded records
95,213 acceptance records, 11,351 under review now
Source
Public data from the CDE acceptance list and under-review list
New acceptances this week
333
Drugs with new generic filings (by drug name, de-duplicated)
41
Accepted this week, now under review
333

DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.

Names with a public page are linked.

New acceptances this week

By application type and drug type

333filings, 57 of them generic

By application type

Application typeFilings
Supplement176
New drug61
Generic57
Import31
Import re-registration7
Unspecified1

By drug type

Drug typeFilings
Chemical drug178
TCM75
Therapeutic biologic68
Unspecified5
Biologic5
Prophylactic biologic2

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

41 drugs with new generic filings; top 10 listed

#DrugNew generic filingsFiling companiesUnder review, all years
1司美格鲁肽注射液 · No verified English name5199
2Mirogabalin Besilate Tablets3264
3Ambroxol Hydrochloride Oral Solution3149
4Rosuvastatin Calcium and Ezetimibe Tablets (I)227
5二硫化硒洗剂 · No verified English name2116
6Brexpiprazole Orally Disintegrating Tablets2112
7恩那度司他片 · No verified English name212
8Topiramate Tablets212
9Sildenafil Citrate Tablets2114
10Polyvinyl Alcohol Eye Drops2126

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

206 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Henan Pu Rui Pharma Co., Ltd. romanized1480
2Eli Lilly and Company640
3Novo Nordisk A/S610
4Xiamen Te Bao Bio Gong Cheng Co., Ltd. romanized610
5Suzhou Te Rui Pharma Co., Ltd. romanized515
6Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized440
7Pfizer Inc.430
8Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized430
9Boehringer Ingelheim International GmbH410
10CSL Behring GmbH410

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Based on changes in CDE's under-review list

Entered review this week
333
Left the under-review list this week
538

Of these, NMPA published approval-document delivery for 281 (including 277 supplemental applications, not counted as new marketing approvals) and notification delivery for 19; the outcome of the other 238 is to be checked.

Most filings leaving review, by company

Most filings leaving review, by company
#Company (first applicant)FilingsDrugs
1Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized112
2Mu Dan Jiang Ling Tai Pharma Co., Ltd. romanized99
3Luo Yang Yi Long Pharma Co., Ltd. romanized77
4Guangdong Tai En Kang Pharmaceutical Factory Co., Ltd. romanized62
5Eli Lilly and Company61
6Hybio Pharmaceutical Co.,Ltd.61
7Qinghai Qi Ying Han Cang Biopharmaceutical Co., Ltd. romanized55
8Shenyang Xing Qi Yan Yao Co., Ltd. romanized52
9Guangzhou Jia Yue Pharmaceuticals Technology Co., Ltd. romanized51
10Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized44

Most filings entering review, by company

Most filings entering review, by company
#Company (first applicant)FilingsDrugs
1Henan Pu Rui Pharma Co., Ltd. romanized148
2Eli Lilly and Company64
3Novo Nordisk A/S61
4Xiamen Te Bao Bio Gong Cheng Co., Ltd. romanized61
5Suzhou Te Rui Pharma Co., Ltd. romanized51
6Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized44
7Pfizer Inc.43
8Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized43
9Boehringer Ingelheim International GmbH41
10CSL Behring GmbH41

DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

99 this week

AcceptedDrugApplicants
2026/11/20Import · Class 1 IPN60340注射液 · No verified English nameJXSL2600326 IPSEN PHARMA; Ipsen (Shanghai) Innovation Pharmaceutical Co. Ltd
2026/11/20Import · Class 2.2 注射用维恩妥尤单抗 · No verified English nameJXSL2600325 Pfizer Inc.; Astellas (China) Investment Co. Ltd.
2026/11/20Import · Class 2.2 注射用维恩妥尤单抗 · No verified English nameJXSL2600324 Pfizer Inc.; Astellas (China) Investment Co. Ltd.
2026/11/20Import · Class 1 Duvakitug注射液 · No verified English nameJXSL2600323 Sanofi-Aventis Recherche & Développement; Sanofi (China) Investment Co. Ltd.
2026/11/20Generic · Class 3 Vardenafil Hydrochloride Orally disintegrating TabletsCYHS2602862 Shandong Loncom Pharmaceutical Co., Ltd.
2026/11/20Generic · Class 3 Diphenhydramine Hydrochloride TabletsCYHS2602861 Jiangsu Vanguard Pharmaceutical Co., Ltd.
2026/11/20Generic · Class 3 Sivelestat Sodium for InjectionCYHS2602860 Nanjing En Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Hai An Pharma Co., Ltd. romanized
2026/11/20New drug · Class 1 注射用BL-M11D1 · No verified English nameCXSL2601297 Chengdu Bai Li Duo Te Bio Pharma Co., Ltd. romanized; Sichuan Baili Pharmaceutical Co., Ltd.
2026/11/20New drug · Class 1 RXIM002 · No verified English nameCXSL2601296 Zhuan Lu Ben (Shanghai) Bio Technology Co., Ltd. romanized
2026/11/20New drug · Class 1 注射用Zilovertamab vedotin · No verified English nameCXSL2601295 Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized
2026/11/20New drug · Class 1 注射用MK-1045 · No verified English nameCXSL2601294 Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized
2026/11/20New drug · Class 1 IB101注射液 · No verified English nameCXSL2601293 Xi Hu Laboratory Technology (Hangzhou) Co., Ltd. romanized
2026/11/20New drug · Class 1 IBI3001 · No verified English nameCXSL2601292 Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized
2026/11/20New drug · Class 2.4 海曲泊帕乙醇胺片 · No verified English nameCXHS2600158 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
2026/11/20New drug · Class Unmapped source value 盐酸凯普拉生注射液 · No verified English nameCXHS2600157 Nanjing Ke Chuang Pharmaceutical Co., Ltd. romanized
2026/11/20New drug · Class 1 氘索昔替尼片 · No verified English nameCXHS2600156 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
2026/11/20New drug · Class 1 氘索昔替尼片 · No verified English nameCXHS2600155 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
2026/11/20New drug · Class 2.2 GLX005 · No verified English nameCXHL2601461 YABAO PHARMACEUTICAL GROUP CO.,LTD
2026/11/20New drug · Class 2.3 BPR-523-X片 · No verified English nameCXHL2601460 Chengdu Brilliant Pharmaceutical Co., Ltd.
2026/11/20New drug · Class 2.3 BPR-523-X片 · No verified English nameCXHL2601459 Chengdu Brilliant Pharmaceutical Co., Ltd.
2026/11/20New drug · Class 1 DAT-1604片 · No verified English nameCXHL2601458 Zhejiang Dan Qing Pharma Technology Co., Ltd. romanized
2026/11/20New drug · Class 1 DAT-1604片 · No verified English nameCXHL2601457 Zhejiang Dan Qing Pharma Technology Co., Ltd. romanized
2026/11/19Generic · Class 3 Colistimethate Sodium for InjectionCYHS2602859 Tianjin Chase Sun Pharmaceutical Co.,Ltd; Sichuan Huiyu Pharmaceutical Co., Ltd.
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602857 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602856 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602855 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
Generic · Class 3 司美格鲁肽注射液 · No verified English name —
Generic · Class 3 司美格鲁肽注射液 · No verified English name —
2026/11/19Generic · Class 3 盐酸氨酮戊酸颗粒剂 · No verified English nameCYHS2602848 Shanghai Fu Dan Zhang Jiang Biopharmaceuticals Co., Ltd. romanized
2026/11/19New drug · Class 1 IBI363 · No verified English nameCXSL2601291 Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized

69 more not listed (at most 30 rows).

For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.